Published in Health Qual Life Outcomes on May 05, 2014
Minimally important difference of the Child Oral Health Impact Profile for children with orofacial anomalies. Health Qual Life Outcomes (2016) 0.84
EuroQol--a new facility for the measurement of health-related quality of life. Health Policy (1990) 59.70
US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care (2005) 9.89
Methods to explain the clinical significance of health status measures. Mayo Clin Proc (2002) 7.00
Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol (2007) 6.24
Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology (2003) 3.75
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes (2007) 3.66
Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology (2006) 2.72
Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler (2007) 1.99
Valuations of EQ-5D health states: are the United States and United Kingdom different? Med Care (2005) 1.95
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Med Care (2010) 1.69
Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol (2013) 1.53
A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry (2005) 1.50
Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest (2008) 1.21
Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes (2005) 1.07
Minimal clinically important differences for the EQ-5D and QWB-SA in Post-traumatic Stress Disorder (PTSD): results from a Doubly Randomized Preference Trial (DRPT). Health Qual Life Outcomes (2013) 1.00
Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. Mult Scler (2011) 0.99
Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler (2010) 0.95
Association of factors influencing health-related quality of life in MS. Acta Neurol Scand (2006) 0.93
A longitudinal comparison of 5 preference-weighted health state classification systems in persons with intervertebral disk herniation. Med Decis Making (2010) 0.89
Prognostic accuracy of clinical prediction rules for early post-pulmonary embolism all-cause mortality: a bivariate meta-analysis. Chest (2015) 1.70
MicroRNAs in diabetes: tiny players in big disease. Cell Physiol Biochem (2009) 1.53
Derivation and validation of the In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) prediction rule. Curr Med Res Opin (2015) 1.02
Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis. PLoS One (2013) 0.93
Recent advances in antimalarial drug development. Med Res Rev (2007) 0.92
Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients. Health Qual Life Outcomes (2013) 0.82
Walking speed and health-related quality of life in multiple sclerosis. Patient (2014) 0.79
2-tert-butyl-8-quinolinamines exhibit potent blood schizontocidal antimalarial activity via inhibition of heme crystallization. Antimicrob Agents Chemother (2007) 0.78
Cancer stem cells: an insight and future perspective. J Cancer Res Ther (2015) 0.77
Transcriptome profiling identifies p53 as a key player during calreticulin deficiency: Implications in lipid accumulation. Cell Cycle (2015) 0.77
NOx and ADMA changes with focal ischemia, amelioration with the chaperonin GroEL. Neurosci Lett (2007) 0.77
Synthesis and optimization of novel and selective muscarinic M(3) receptor antagonists. Bioorg Med Chem Lett (2007) 0.77
Impact of angina frequency on health utility values of patients with chronic stable angina. Health Qual Life Outcomes (2014) 0.75
Smoking cessation. Clin Pharmacol (2012) 0.75
Mobility, walking and physical activity in persons with multiple sclerosis. Curr Med Res Opin (2014) 0.75
Bioresolution of benzyl glycidyl ether using whole cells of Bacillus alcalophilus. J Basic Microbiol (2011) 0.75